' Aspirationally Resectable ' ? Neoadjuvant Tx Evolves in NSCLC ' Aspirationally Resectable ' ? Neoadjuvant Tx Evolves in NSCLC

H. Jack West, MD, and Julia Rotow, MD, discuss clinical implications of thoracic oncology research presented at ASCO 2023.Medscape Oncology
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news